May 05, 2023

Limited Surgery Plus Proton Therapy in Pediatric and Adolescent Patients With Craniopharyngioma

In a phase II trial (RT2CR) reported in The Lancet Oncology, Thomas E. Merchant, DO, and colleagues found that limited surgery plus proton therapy was associated with a high rate of disease control an...

The ASCO Post

March 28, 2024

Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma

On December 13, 2023, eflornithine (Iwilfin), an ornithine decarboxylase inhibitor, was approved for adult and pediatric patients with high-risk neuroblastoma with at least a partial response to prior...

The ASCO Post

November 09, 2023

Role of the Advanced Practitioner in Clinical Research

Advanced practitioners are key members of the oncology care team, and their numbers and significance continue to expand. While the role of the AP has become well defined in everyday clinical practice,...

JADPRO

February 08, 2023

Higher Rate of Clonal Hematopoiesis in Pediatric Cancer Survivors May Be Linked With Treatment-Induced STAT3 Gene Mutations and Risk of Adverse Long-Term Outcomes

A large study by researchers at St. Jude Children’s Research Hospital has identified a higher rate of clonal hematopoiesis as well as significant enrichment in treatment-related STAT3 gene mutations i...

The ASCO Post

October 01, 2023

Dana-Farber Research Publication 10.1.2023

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors.

Dana-Farber

August 13, 2024

FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park.

The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center.

Roswell Park Comprehensive Cancer Center

May 23, 2024

Clinical Trial Mounts Two-Pronged Attack Against Relapsed/Refractory Pediatric Sarcomas

In recent years investigators have launched a growing number of clinical trials evaluating the efficacy of combining chemotherapy and immunotherapy in a two-pronged attack against cancer.

Roswell Park Comprehensive Cancer Center

February 06, 2025

Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL

A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-c...

The ASCO Post

September 03, 2024

Adolescent Glioma Subtype Responds to CDK4/6 Inhibitor

CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to new research from Dana-Farber Cancer Institute and the Institute of Cancer Research in London.

Dana-Farber